Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Immunol
Main Authors: Seyed Jafari, S. Morteza, Feldmeyer, Laurence, Bossart, Simon, Simon, Dagmar, Schlapbach, Christoph, Borradori, Luca
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Immunology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7879677/
https://ncbi.nlm.nih.gov/pubmed/33584689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.611549
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki